Market Research Report
Global Biosimilar's Market - 2018 - 2025
|Published by||DataM Intelligence||Product code||757889|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Biosimilar's Market - 2018 - 2025|
|Published: October 1, 2018||Content info: 130-180 Pages||
The global biosimilar's market is estimated to be USD XX billion in 2017 and the market is estimated to grow at a double digit growth rate in the forecasted period 2018-2021.
Growing strategic partnerships among the companies for the development of the biosimilars, high growth of the biosimilars across the world, outsourcing of the biosimilars are some of the key trends observed in the global biosimilars market.
Low product development costs of the biosimilars (~200-300 million) compared to other biologics products (~700-800 million), less time taken for the products approval (~2-3 years less than biologics), growing demand for cost effective treatment, growing patent expiries, favourable reimbursements policies for the biosimilars, and strong product pipeline for the biosimilars are some of the major factors favouring the growth of the biosimilars. Limited availability of biosimilars, challenges in clinicals trials, and high risks of product failure are some of the key challenges in the biosimilars market.
Segmentation by Application
The Biosimilars market by application is segmented into oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and others. Oncology biosmiliars is one of the largest and the fastest growing market for biosimilars in the forecasted period. Large numbers of biosimilars are expected to lose its patent during the forecasted period while oncology biosimilars are estimated to launch during the same period strengthening the market for oncolytic biosimilars.
Segmentation by Geography
By geography, Europe dominated the global biosimilars market share in 2017. Regulatory support for the market and raising incidents for cancer in the European region are some of the major factors driving the European market. The market for biosimilars in the United Kingdom is mature, well established, and easy to enter making it one of the fastest growing regions in the European region. United States market is not favourable for the biosimilars due to poor access to biosimilars, and unconductive regulatory environment and because of which the market is growing at the slower rate but is estimated to grow in the forecasted period. Emerging nations have high presence of biosimilars and are highly supporting the growth of the market.
Scope of the Report
Segmentation by Therapy Type
Recombinant Non-Glycosylated Proteins
Human growth hormone
Granulocyte colony-stimulating factor
Recombinant Glycosylated Proteins
Segmentation by Application
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Segmentation by End User
The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.